Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5389958 | 0.93 | TACR1 (0.52) | TACR1PAK1MAPTGPR119STS | |
| SCHEMBL5395886 | 0.89 | TACR1 (0.43) | TACR1PAK1MAPTSMN1; SMN2GPR119 | |
| SCHEMBL5409066 | 0.89 | TACR1 (0.43) | TACR1PAK1GPR119STSJAK2 | |
| SCHEMBL5398236 | 0.89 | TACR1 (0.57) | TACR1 | |
| SCHEMBL6259747 | 0.87 | TACR1 (0.45) | TACR1SMN1; SMN2 | |
| SCHEMBL5398539 | 0.85 | TACR1 (0.49) | TACR1PAK1MAPTGPR119LMNA | |
| SCHEMBL5398565 | 0.84 | TACR1 (0.52) | TACR1MAPTSMN1; SMN2GPR119JAK2 | |
| SCHEMBL5390865 | 0.82 | TACR1 (0.50) | TACR1MAPTSMN1; SMN2GPR119STS | |
| SCHEMBL5391942 | 0.81 | TACR1 (0.45) | TACR1PAK1MAPTGPR119LMNA | |
| SCHEMBL5390778 | 0.81 | TACR1 (0.62) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214680-B2 | 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| US-20040242592-A1 | 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242592-A1 | 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | SLC6A4, TPH1, HTR1D | TACR1 49/4885PAK1 2048/4885MAPT 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.